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Background: Cumulative evidence from epidemiological, preclinical and clinical studies suggests estrogens
may have psychoprotective effects in schizophrenic patients. Selective Estrogen Receptor Modulators could have
therapeutic benefits in schizophrenia for both sexes without being hazardous to gynecological tissues or having
feminizing effects. Few studies have been conducted regarding the effects of raloxifene on postmenopausal women
suffering from schizophrenia. We conducted this placebo-controlled trial to compare the add-on effect of raloxifene
to risperidone versus risperidone with placebo.
Methods: This was an 8-week, parallel-group, placebo-controlled trial undertaken at two universities affiliated
psychiatric Hospitals in Iran. Forty-six postmenopausal women with the definite diagnosis of schizophrenia were
enrolled in the study. Patients received risperidone (6 mg/day in 3 divided doses) combined with either placebo
(N = 23) or 120 mg/day of raloxifene (N = 23) for 8 weeks. Patients were assessed by a psychiatrist at baseline and at 2
and 8 weeks after the start of medical therapy. Efficacy was defined as the change from baseline to endpoint in score
on Positive and Negative Syndrome Scale (PANSS).
Results: For PANSS scores, the main effect comparing two types of intervention was not significant [F (1, 48) = 1.77,
p = 0.18]. For positive subscale scores, there was marginal significant interaction between intervention type and time
[F (2, 47) = 2.93, p = 0.06] and there was substantial main effect for time [F (2, 47) = 24.39, p = 0.001] within both groups
showing reduction in positive subscale scores across the three time periods. In addition, the main effect comparing two
types of intervention was significant [F (1, 48) = 3.78, p = 0.02]. On the other hand, for negative subscale scores, the
main effect comparing two types of intervention was not significant [F (1, 48) = 1.43, p = 0.23]. For general subscale
scores, the main effect comparing two types of intervention was not significant [F (1, 48) = 0.03, p = 0.86].
Conclusions: According to our findings, raloxifene as an adjunctive treatment to risperidone was only superior in
improvement of positive symptoms and it was not effective in treating negative and general psychopathology
symptoms.
Trial registration: The trial was registered at the Iranian registry of clinical trials: IRCT201205131556N42
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Cumulative evidence from epidemiological, preclinical
and clinical studies suggests estrogens may provoke
psychoprotective effects in schizophrenic patients [1].
In addition, Selective Estrogen Receptor Modulators
(SERMs) could have therapeutic benefits on both sexes
with schizophrenia without any hazard to gynecological
tissues or feminizing effects [1]. There are several lines
of evidence that support the estrogen hypothesis of
schizophrenia [2]. Most antipsychotics cause prolactin-
inducing effects, and ensuing negative feedback on
estrogen levels [2]. Sex differences in the incidence,
onset and course of schizophrenia have led to the
hypothesis that estrogens play a protective role in the
pathophysiology of this disorder [3]. Estrogen treatment
may boost the recovery of schizophrenia in women.
However, adverse effects on uterine and breast tissue
and other physical side effects may limit the long-term
therapeutic use of estrogen [4-6]. Raloxifene hydrochlor-
ide is a selective estrogen receptor modulator that acts as
an estrogen antagonist in breast tissue and may have
agonistic actions in the brain, potentially offering mental
health benefits with few estrogenic side effects [4].
Prognosis and severity of schizophrenia is different
between males and females and as a result, it is suggested
that estrogen may play a role in the pathogenesis of
schizophrenia [1,3]. sex differences is a fascinating aspect
of schizophrenia, which have been described for nearly
all features of the illness, including the peak age of
onset, symptoms and treatment response [7]. Estradiol
and some SERMs are neuroprotective in a variety of
experimental models of neurodegeneration; they could
lessen the inflammatory response of glial cells, decrease
anxiety and depression, and endorse cognition. More-
over, they are able to modulate synaptic plasticity in the
hippocampus of rodents [8]; however, long term estrogen
application may cause significant complications especially
in menopausal women. Therefore, administration of Select-
ive Estrogen Receptor Modulators (SERMs) may reduce
such side effects. Raloxifene is a SERM that has similar
dopaminergic and serotonergic effects as estrogen. Few
studies have been conducted regarding the effects of
raloxifene on postmenopausal women suffering from
schizophrenia [9,10]. However, the sample size of these
studies was relatively small [9.10]. We conducted this
placebo-controlled trial to compare the add-on effect of




This was an 8-week, parallel-group, placebo-controlled
trial undertaken at two universities affiliated psychiatric
Hospitals in Iran (Roozbeh and Razi Hospital) fromJune 2012 to December 2013. The trial protocol was
approved by the Institutional Review Board (IRB) of
Tehran University of Medical Science (Grant No: 17215)
and was conducted in agreement with the Declaration
of Helsinki and its subsequent revisions. The trial was
registered at the Iranian registry of clinical trials (www.
irct.ir; registration number: (IRCT201205131556N42).
Written informed consent was obtained from all eligible
patients and/or their legally authorized representatives.
Patients were informed that they are free to withdraw
from the study at any time without any influence on their
relationship with their health care provider.
Study population
Forty-six postmenopausal women with the definite diag-
nosis of schizophrenia were enrolled in the study. The
diagnosis of schizophrenia was made according to DSM-
IV TR. Diagnosis was made based on a Structured Clinical
Interview for DSM-IV-TR Axis I Disorders (SCID) and
was confirmed with chart review and senior physician
interview. Inclusion criteria were postmenopausal (be
in postmenopause is defined as period of one year
spontaneous amenorrhea, a serum FSH level of >20 and
clinical symptoms such as hot flashes,…) women who
met the diagnostic criteria for schizophrenia according to
DSM IV-TR consisting of Positive and Negative Syndrome
Scale (PANSS) [11] score above 60 and disease onset over
2 years. Exclusion criteria were the concurrent presence of
neurologic or organic disorders; IQ lower than 70; illicit
drug use in past 6 months, consumption of antipsychotic
drugs in the previous week or a long-acting antipsychotic
drug in previous 2 months, receiving any antidepressant
and mood stabilizer drugs during the trial, former hormone
replace therapy, electroconvulsive therapy in past 2 weeks;
endocrine abnormality; hepatic or renal dysfunction; and
history of thromboemboli, abnormal uterine bleeding or
breast and uterine cancer, and stroke.
Study design
Forty-six postmenopausal women with DSM-IV-TR diag-
nosed chronic schizophrenia received risperidone (6 mg/day
in 3 divided doses) (Janssen Pharmaceuticals, Toronto,
Canada; 2 mg tablet) combined with either placebo (N = 23)
or 120 mg/day of raloxifene (Eli Lilly) (N = 23) for 8 weeks.
Patients were assessed by a psychiatrist at baseline and at
2 and 8 weeks after the start of medical therapy. Efficacy
was defined as the change from baseline to endpoint in
score on PANSS.
Outcome measurement
PANSS is one of the most important rating tools for
computing symptom severity in patients with schizo-
phrenia. It comprises 3 subscales (positive scale, negative
scale, and general psychotherapy scale) with 30 items in
Figure 1 Trial flow diagram of adjunctive Raloxifene
versus placebo.
Kianimehr et al. DARU Journal of Pharmaceutical Sciences 2014, 22:55 Page 3 of 7
http://www.darujps.com/content/22/1/55total ranging in score between 1 and 7 which leads to a
minimum total score of 30. PANSS has been used in a
number of trials in Iran [12-15]. The mean decline in
PANSS scale as well as subscales from baseline was
regarded as the main outcome measure of response in
schizophrenia to treatment. The scale was measured at
baseline, week 2 and week 8. Efficacy will be defined as
change from baseline to endpoint in score on PANSS.
Adverse events were evaluated using a 25 –item checklist
and Extra-pyramidal Symptoms Rating Scale (ESRS) [16].
Statistical analysis
SPSS software, version 20.0 for Windows, was used to
analyze the data. Continuous data are presented as
mean ± standard deviation (SD). We used Kolmogorov-
Smirnov Z test to determine the normal distribution of
all continuous variables and due to normal distribution
of PNSS score and subscales (positive, negative, general),
we used parametrical tests to analyze data. A mixed
between-within subjects analysis of variance was conducted
to assess the impact of two different interventions (Risperi-
done + Raloxifene, Risperidone + placebo) on patient scores
on PANSS score, positive subscale, negative subscale, and
general psychotherapy subscale, across three time periods
(the start of study, week 2, and week 8).
Results
Figure 1 shows flow diagram of the patients. The mean
age (±SD) of the raloxifene group was 61.96 ± 4.49 years
versus 60.44 ± 5.28 years in the placebo group (non sig-
nificant). Demographic data of the patients is presented
in Table 1.
For PANSS scores, there was no significant interaction
between intervention type and time [Wilks’ Lambda = 0.89,
F (2, 47) = 2.79, p = 0.07]. There was substantial main effect
for time [Wilks’ Lambda = 0.36, F (2, 47) = 42.56, p < 0.01]
within both groups showing a reduction in PANSS scores
across three time periods (Table 2, Figure 2). Furthermore,
the main effect comparing two types of intervention was
not significant [F (1, 48) = 1.77, p = 0.18].
For positive subscale scores, there was marginal signifi-
cant interaction between intervention type and time [Wilks’
Lambda = 0.89, F (2, 47) = 2.93, p = 0.06] and there was
substantial main effect for time [Wilks’ Lambda = 0.44,
F (2, 47) = 24.39, p < 0.01] within both groups showing a
reduction in positive subscale scores across the three
time periods (Table 2, Figure 3). In addition, the main
effect comparing two types of intervention was significant
[F (1, 48) = 3.78, p = 0.02] suggesting superior effectiveness
of Risperidone plus Raloxifene over Risperidone plus
Placebo.
For negative subscale scores, there was no significant
interaction between intervention type and time [Wilks’
Lambda = 0.99, F (2, 47) = 0.12, p = 0.73]. There wassubstantial main effect for time [Wilks’ Lambda = 0.46,
F (2, 47) = 55.65, p < 0.01] within both groups showing
a reduction in negative subscale scores across three time
periods (Table 2, Figure 4). Additionally, the main effect
comparing two types of intervention was not significant
[F (1, 48) = 1.43, p = 0.23] suggesting no difference in effect-
iveness of the two therapies on negative subscale scores.
For general subscale scores, there was significant in-
teraction between intervention type and time [Wilks’
Lambda = 0.78, F (2, 47) = 6.78, p < 0.01]. There was
substantial main effect for time [Wilks’ Lambda = 0.34,
F (2, 47) = 46.13, p < 0.01] within both groups showing
a reduction in general subscale scores across the three
time periods (Table 2, Figure 5). However, the main effect
comparing two types of intervention was not significant
[F (1, 48) = 0.03, p = 0.86] suggesting no difference in the
effectiveness of the two therapies on general subscale
scores.
Main adverse events included constipation (3 patients in
Raloxifene group and 2 patients in placebo group), tremor
(1 in each group), dry mouth (2 patients in raloxifene
group), restless leg syndrome (1 patient in Raloxifene
Table 1 Demographic data of the raloxifene group versus the placebo group
Risperidone + Raloxifene group (N = 25) Risperidone + Placebo group (N = 25) p-value
Age (±SD) 61.96 ± 4.49 60.44 ± 5.28 p > 0.05
Education Illiterate 4 (36.36%) 7 (63.64%) p > 0.05
School 17 (51.52%) 16 (48.48%)
University 3 (50%) 3 (50%)
Positive family history 13 (42%) 15 (60%) p > 0.05
Age of onset 34.96 ± 11.69 29.40 ± 8.57 p > 0.05
Duration 17.24 ± 12.03 13.64 ± 12.41 p > 0.05
Previous treatment Risperidone 7 (41.12%) 10 (58.88%) p > 0.05
Other atypical 3 (75.0%) 1 (25.0%)
Typical 11 (50.0%) 11 (50.0%)
Combination 4 (57.14%) 3 (42.86%)
IQ Normal 24 (52.17%) 22 (47.83%) p > 0.05
Borderline 1 (25.0%) 3 (75.0%)
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of appetite (1 patient in placebo group). In addition, there
was no ESRS difference between the two groups at weeks
2 and 8 [F (1, 48) = 1.04, p = 0.30].
Discussion
Adjunctive therapy and polypharmacy is used routinely
for several chronic diseases. Medications with different
mechanisms of action are used in polypharmacy. The
use of adjunctive therapy in schizophrenia has been a
major concern especially in recent years. The potential
therapeutic efficacy of estrogens in schizophrenia is being
identified and Selective Estrogen Receptor Modulators
(SERMs) seem to be a better option in view of safety
concerns. According to our findings, Raloxifene as an
adjunctive treatment to risperidone was only superiorTable 2 PANSS and subscale scores for the intervention type
Rispe
Time period Mean
PANSS score Week 0 105.52
Week 2 89.08
Week 8 68.32
Positive subscale Week 0 25.76
Week 2 20.92
Week 8 14.32
Negative subscale Week 0 28.04
Week 2 24.88
Week 8 19.60
General Psychopathology subscale Week 0 50.44
Week 2 43.56
Week 8 34.56for positive symptoms and it was not effective in treating
negative and general psychopathology symptoms.
Recently, some studies have pointed to the adjunctive
efficacy of raloxifene in improving schizophrenic symptoms
[17]. In a 12-week, double-blind, randomized, placebo-
controlled study [10], 33 postmenopausal women with
schizophrenia were randomized to receive either adjuvant
raloxifene (16 women) or adjuvant placebo (17 women)
for three months. The addition of raloxifene produced
significant differences in some aspects of memory and
executive function in patients treated with raloxifene.
In another 12-week, double-blind, randomized, pla-
cebo-controlled study, 33 postmenopausal women with
schizophrenia and prominent negative symptoms were
randomized to either adjunctive raloxifene or adjunctive
placebo for 12 weeks [9]. The addition of raloxifeneacross three time periods
ridone + Raloxifene (n = 25) Risperidone + Placebo (n = 25)
± SD Mean ± SD
± 16.96 105.00 ± 11.68
± 16.14 94.16 ± 19.78
± 21.04 82.00 ± 26.14
± 8.00 26.68 ± 7.04
± 5.41 24.28 ± 6.33
± 4.33 21.12 ± 7.07
± 8.64 30.76 ± 9.09
± 8.76 28.12 ± 10.88
± 8.66 23.08 ± 12.08
± 9.92 47.52 ± 6.46
± 9.30 41.88 ± 9.76
± 10.78 37.84 ± 11.89
Figure 2 PANSS scores for the intervention type across three time
periods (Raloxifene group: solid line, Placebo group: dashed line).
Figure 4 Negative subscale scores for the intervention type
across three time periods (Raloxifene group: solid line, Placebo
group: dashed line).
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reduced negative, positive, and general psychopathology
symptoms compared to the placebo group.
In a randomized clinical trial [4], 35 postmenopausal
women with schizophrenia received 120 mg/day adjunctive
raloxifene compared to either adjunctive raloxifene HCl
(60 mg/day) or placebo. A significantly greater recovery of
total and general PANSS symptoms was noted in patients
receiving 120 mg/day adjunctive raloxifene compared to
either 60 mg/day adjunctive raloxifene HCl or placebo.
In addition, adjunctive Raloxifene has been successfully
used in single case reports for menstruating women
suffering from resistant schizophrenia. A 29-year-old
woman, with drug-resistant schizophrenia, experienced
significant improvement in socio-occupational function-
ing, with reduction in symptom severity, over a 7-month
follow-up period, [18].
It is significant that we encountered no adverse effects
in the raloxifene group compared to the placebo group.
The safer raloxifene profile compared with estrogenic
compounds, makes it a preferred drug when adjunctiveFigure 3 Positive subscale scores for the intervention type across
three time periods (Raloxifene group: solid line, Placebo group:
dashed line).hormonal therapy of schizophrenia for post-menopausal
women is considered. The lack of adverse effects on
breast and uterine tissue is an imperative advantage of
Raloxifene over estrogen [19].
The ovarian hormone 17β-estradiol acts in the central
nervous system to regulate neuroendocrine events and
reproduction. Estradiol controls gene expression, neuronal
survival, neuronal and glial differentiation, and synaptic
transmission and has anti-inflammatory, protective and
reparative properties in the brain [20,21]. A number of
studies seem to indicate that raloxifene acts on brain
dopamine and serotonin systems in a way that is similar
to that of conjugated estrogens [22].
It is proposed that conjugated estrogens may exercise
their therapeutic potential either by modulating brain
neurotransmission or through neuroprotective effects.
On the other hand, the incidence of schizophrenia in
men is consistently observed to be approximately 1.5
times higher than its in women [23] and there is a male
predominance in incidence in the early twenties, but aFigure 5 General Psychopathology subscale scores for the
intervention type across three time periods (Raloxifene group:
solid line, Placebo group: dashed line).
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may have an impact on schizophrenia by several mecha-
nisms. Short-term, it seems to have fast membrane effects
by modifying functional activity in the dopaminergic
synapse; for longer periods, it may appear to have genomic
effects by altering synthesis at dopamine receptors.
There is also evidence to suggest that estrogen alters
serotonergic systems. Estrogen can also promote neur-
onal regeneration and block mechanisms of neuronal
death [4]. In addition, numerous studies have described
association between serotonin 1A receptor and major
psychiatric disorders, such as schizophrenia and bipolar
disorder [25]. Both serotonin and estrogen have been
involved in modulation of mood and cognition. Even
though substantial functional relations between estro-
gen and serotonin are recognized, the nature of their
relationship has not been fully illuminated [26]. This
study has some limitations which should be considered.
The sample size was relatively small and the study
course and follow-up period were relatively short. We
did not measure the effect of raloxifene on menopausal
symptoms as well. Furthermore, lack of cognitive assess-
ments is another limitation of the present study.
Conclusions
In conclusion, it seems that according to our findings,
raloxifene as an adjunctive treatment was shown to be
superior to placebo in improving the positive symptoms
in patients receiving risperidone. However, this drug
did not show a benefit in treating the negative and
general symptoms of schizophrenia when was added
to risperidone therapy.
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